{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:50:54Z","timestamp":1774612254367,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T00:00:00Z","timestamp":1137542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To compare the lipid and metabolic effects, efficacy, and safety of twice\u2010daily regimens of Trizivir<jats:sup>\u00ae<\/jats:sup> (abacavir 300\u2003mg\/lamivudine 150\u2003mg\/zidovudine 300\u2003mg triple nucleoside tablet; TZV), Combivir<jats:sup>\u00ae<\/jats:sup> (lamivudine 150\u2003mg\/zidovudine 300\u2003mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4\u2003T)+lamivudine (3TC)+NFV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>An international, phase 4, open\u2010label, parallel\u2010group, 34\u2010centre study was conducted in 254 non\u2010diabetic, antiretroviral\u2010naive, HIV\u2010infected out\u2010patients with an HIV\u20101 RNA level of &gt;1000 HIV\u20101 RNA copies\/mL and \u2264200 000 copies\/mL and a CD4 cell count of &gt;50 cells\/\u03bcL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were randomized 1\u2003:\u20031\u2003:\u20031 to TZV twice daily (<jats:italic>n<\/jats:italic>=85), COM\/NFV 1250\u2003mg twice daily (<jats:italic>n<\/jats:italic>=88), or d4T 40\u2003mg+3TC 150\u2003mg+NFV 1250\u2003mg twice daily (<jats:italic>n<\/jats:italic>=81) for 96 weeks. Treatments were compared using analysis of covariance (ANCOVA) with regard to changes from baseline in fasting lipids in the total population and in sex and ethnic subgroups. The proportions of patients achieving HIV\u20101 RNA &lt;50 and &lt;400 copies\/mL were compared using a 95% confidence interval (CI) on the difference between proportions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study population was diverse (50% female, 40% black and 37% Hispanic). Mean baseline low\u2010density lipoprotein (LDL) cholesterol was 99\u2003mg\/dL, HIV\u20101 RNA was 4.43 log<jats:sub>10<\/jats:sub> copies\/mL and CD4 cell count was 355 cells\/\u03bcL. At week 96, fasting LDL cholesterol changed minimally in the TZV group [least square mean (LSM) change from baseline, \u22128\u2003mg\/dL], but increased with d4T\/3TC\/NFV and COM\/NFV (+29 and +19\u2003mg\/dL, respectively; <jats:italic>P<\/jats:italic>&lt;0.001 versus TZV). Week 96 LDL\u2010cholesterol levels were significantly lower in the TZV group than in the other two treatment groups in women and men and lower than in the d4T\/3TC\/NFV group in Hispanic and black patients. In black patients, the week\u201096 LSM change from baseline in LDL cholesterol was significantly less with TZV than with d4T\/3TC\/NFV (+1 vs+39\u2003mg\/dL; <jats:italic>P<\/jats:italic>=0.003). Total cholesterol&gt;200\u2003mg\/dL occurred in a smaller proportion of patients receiving TZV (30%) compared with COM\/NFV (50%) or d4T\/3TC\/NFV (60%; <jats:italic>P<\/jats:italic>=0.005 vs TZV). High\u2010density lipoprotein (HDL) cholesterol did not change markedly with any treatment. Although triglycerides increased, they changed least in women and Hispanic patients receiving TZV. Virological and CD4 responses to the treatments were similar in the total population and in the subgroups. Diarrhoea was reported more often in the NFV arms and nausea in the ZDV arms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Over 96 weeks, TZV twice daily has significantly less effect on LDL cholesterol than COM\/NFV or d4T\/3TC\/NFV twice daily, especially in women and black patients, and is associated with similar virological and CD4 responses.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2006.00346.x","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T11:29:06Z","timestamp":1137583746000},"page":"85-98","source":"Crossref","is-referenced-by-count":62,"title":["A prospective, 96\u2010week study of the impact of Trizivir<sup>\u00ae<\/sup>, Combivir<sup>\u00ae<\/sup>\/nelfinavir, and lamivudine\/stavudine\/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral\u2010naive patients: effect of sex and ethnicity"],"prefix":"10.1111","volume":"7","author":[{"given":"PN","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rodriguez\u2010French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KT","family":"Tashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Averitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PG","family":"Wannamaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VC","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MS","family":"Shaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GE","family":"Pakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KA","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the ESS40002 study team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa011565"},{"key":"e_1_2_6_3_2","volume-title":"AIDS Epidemic Update, December 2004","author":"UNAIDS\/WHO","year":"2004"},{"key":"e_1_2_6_4_2","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC)","volume":"15","year":"2004","journal-title":"HIV\/AIDS Surveillance Report"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.9.1186"},{"key":"e_1_2_6_6_2","first-page":"221","article-title":"Current management challenges in HIV","volume":"17","author":"Hicks C","year":"2003","journal-title":"tolerability of antiretrovirals and metabolic complications"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030218"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031772"},{"key":"e_1_2_6_10_2","first-page":"163","article-title":"Triple nucleoside combination zidovudine\/lamivudine\/abacavir versus zidovudine\/lamivudine\/nelfinavir as first\u2010line therapy in HIV\u20101\u2010infected adults","volume":"8","author":"Matheron S","year":"2003","journal-title":"a randomized trial"},{"key":"e_1_2_6_11_2","first-page":"1103","article-title":"Triple nucleoside treatment with abacavir plus the lamivudine\/zidovudine combination tablet (COM) compared to indinavir\/COM in antiretroviral therapy\u2010na\u00efve adults","volume":"20","author":"Vibhagool A","year":"2004","journal-title":"results of a 48-week open-label, equivalence trial (CNA3014)"},{"key":"e_1_2_6_12_2","first-page":"1155","article-title":"Abacavir\u2010lamivudine\u2010zidovudine vs indinavir\u2010lamivudine\u2010zidovudine in antiretroviral\u2010na\u00efve HIV\u2010infected adults","volume":"285","author":"Staszewski S","year":"2001","journal-title":"a randomized equivalence trial"},{"key":"e_1_2_6_13_2","first-page":"613","article-title":"Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)\u2010infected adults receiving antiretroviral therapy","volume":"37","author":"Dub\u00e9 MP","year":"2003","journal-title":"recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200108170-00009"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/340312"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060020-00015"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346030-00010"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00008"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1310\/F2V7-3R46-VX6J-241R"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131332.30548.92"},{"key":"e_1_2_6_21_2","unstructured":"Garris C Griffith S Mair Cet al.Data on File (APV30002 Clinical Study Report). Glaxo Wellcome Research Triangle Park NC 2002."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059030-00014"},{"key":"e_1_2_6_23_2","first-page":"L35","article-title":"Increased levels of post\u2010prandial triglyceride\u2010rich lipoproteins in patients taking HIV protease inhibitors","volume":"7","author":"Merwood MA","year":"2002","journal-title":"Antiviral Ther"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.7.700"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/108729103321655863"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00042560-200201010-00003","article-title":"Body habitus changes and metabolic alterations in protease inhibitor\u2010naive HIV\u20101\u2010infected patients treated with two nucleoside reverse transcriptase inhibitors","volume":"29","author":"Galli M","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"e_1_2_6_27_2","unstructured":"GallantJ StaszewskiAS PozniakAet al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) na\u00efve patients: a 48\u2010week interim analysis.42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego CA September 2002 [Abstract LB\u20102]."},{"key":"e_1_2_6_28_2","unstructured":"ClotetB CarmenaJ PulidoF LuqueI.Adherence to and general satisfaction with TRIZIVIR\u2122 in HIV\u20101 patients.6th International Conference on Drug Therapy in HIV Infection. Glasgow UK November 2002 [Abstract\/Poster P104]."},{"key":"e_1_2_6_29_2","unstructured":"GattiAM ArpinelliF Viscon\u00e0G PanebiancoR RizzardiniG.On behalf of the ADEQUA Study Team. Impact of less complex HIV\u2010therapy on adherence and quality of life: ADEQUA survey.6th International Conference on Drug Therapy in HIV Infection. Glasgow UK November 2002 [Abstract\/Poster 96]."},{"key":"e_1_2_6_30_2","unstructured":"Division of AIDS. Trizivir compared to efavirenz plus Combivir. 48 weeks interim study results from ACTG5095 March 10 2003.http:\/\/www.natap.org\/2003\/march\/031103\u20102.htm2003."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207050-00005"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2006.00346.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2006.00346.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:58:18Z","timestamp":1696852698000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2006.00346.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,18]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1468-1293.2006.00346.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2006.00346.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,18]]}}}